Positive news concerning the pharmaceutical product Eletriptan EQL Pharma
The pharmaceutical product Eletriptan EQL Pharma was approved Monday within the framework of a decentralized procedure (a common approval procedure used when more than one country is involved). National approvals for Sweden and Denmark are expected within approximately a month. Eletriptan EQL Pharma belongs to a group of medicines called Selective Serotonin receptor (5HT1) agonists. Eletriptan is used to treat migraine headache with or without aura in adults. The total turnover in Sweden and Denmark is approximately 15 MSEK annually. In Denmark, there are two generic competitors on